Back to results
US 6,716,824 B1Granted
Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
OwnerF. Charles Brunicardiinventor
Life of this patent
Estimating the term…
Abstract
This invention relates to a recombinant nucleic acid for an RIP-tk (rat insulin promoter-thymidine kinase) construct that selectively targets insulin secreting cells, such as β-cells, PDX-1 positive human pancreatic ductal carcinomas, and other cells containing certain transcription factors. The present invention is useful in the treatment of pancreatic cancers, such as β-cell insulinomas.
Claims3
A method of treating pancreatic adenocarcinoma in a subject, comprising:
- a) directly administering to a subject a nucleic acid comprising a vector with an insulin promoter having SEQ ID No. 1 operatively coupled to a cytotoxic gene, wherein the cytotoxic gene is thereby expressed in a pancreatic adenocarcinoma cell,
- b) administering a pro-drug to said subject, wherein the prodrug is converted to a cytotoxic compound by the action of the protein encoded by said cytotoxic gene and thereby killing the pancreatic adenocarcinoma cell.
Dependencies are inferred from the claim text.